Literature DB >> 32975459

School performance, psychiatric comorbidity, and healthcare utilization in pediatric multiple sclerosis: A nationwide population-based observational study.

Magnus Spangsberg Boesen1, Morten Blinkenberg2, Lau Caspar Thygesen3, Frank Eriksson4, Melinda Magyari5.   

Abstract

BACKGROUND: Pediatric multiple sclerosis (MS) may hamper educational achievements due to psychiatric comorbidity and cognitive impairment. Our aims were to investigate school performance, psychiatric comorbidity, and healthcare utilization following pediatric MS and to differentiate between disability in MS and that arising from a non-brain-related chronic disease.
METHODS: We included all children (<18 years) with MS onset during 2008-2015 in Denmark with a medical record-validated MS diagnosis. The control groups were children from the general population or children with non-brain-related chronic diseases. Outcomes were register-based on 9-12 grade point average, psychiatric comorbidity, and healthcare visits.
RESULTS: Cohorts were children with MS (n = 92), control children matched to children with MS (n = 920), children with non-brain-related chronic diseases (n = 9108), and "healthy" children with neither MS nor brain-related chronic disease (n = 811,464). School performance in grades 9-12 was similar, but children with MS compared to those with non-brain-related chronic disease had an almost doubled hazard for psychiatric comorbidity (hazard ratio = 1.87; 95% confidence interval = 1.38-2.53; p < 0.0001) and a higher rate of all hospital visits (p < 0.0001) but a lower rate of hospital admissions (p = 0.001).
CONCLUSION: Children with MS have a seemingly standard school performance but increased psychiatric comorbidity and a high rate of healthcare utilization.

Entities:  

Keywords:  School performance; academic; education; healthcare utilization; multiple sclerosis; pediatric; psychiatric

Year:  2020        PMID: 32975459     DOI: 10.1177/1352458520959673

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study.

Authors:  Lauren Krupp; Brenda Banwell; Tanuja Chitnis; Kumaran Deiva; Jutta Gaertner; Angelo Ghezzi; Peter Huppke; Emmanuelle Waubant; Virginia DeLasHeras; Amin Azmon; Rajesh Karan
Journal:  BMJ Neurol Open       Date:  2022-02-24

Review 2.  Cognitive Issues in Pediatric Multiple Sclerosis.

Authors:  Emilio Portaccio; Ermelinda De Meo; Angelo Bellinvia; Maria Pia Amato
Journal:  Brain Sci       Date:  2021-03-30

Review 3.  Needs and Experiences of Children and Adolescents with Pediatric Multiple Sclerosis and Their Caregivers: A Systematic Review.

Authors:  Shashank Ghai; Elisabeth Kasilingam; Roberta Lanzillo; Masa Malenica; Vincent van Pesch; Niamh Caitlin Burke; Antonio Carotenuto; Rebecca Maguire
Journal:  Children (Basel)       Date:  2021-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.